Alessandro Rondina

Dr. Alessandro Rondina

University of Brescia
orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 November 2021 in Cells
Verified
Journal Article
Open access
PDF file
Alessandro RondinaAlessandro Rondina
Alessandro Rondina
Paola FossaPaola Fossa
Paola Fossa
AOAlessandro Orro
Alessandro Orro
LMLuciano Milanesi
Luciano Milanesi
ANTONELLA DE PALMAANTONELLA DE PALMA
ANTONELLA DE PALMA
Pasqualina D'ursiPasqualina D'ursi
Pasqualina D'ursi
Boron Neutron Capture Therapy (BNCT) is a tumor cell-selective radiotherapy based on a nuclear reaction that occurs when the isotope boron-10 (10B) is radiated by low-energy thermal neutrons or epithermal neutrons, triggering a nuclear fission response and enabling a selective administration of irradiation to cells. Hence, we need to create novel delivery agents containing 10B with high tumor selectivity, but also exhibiting low intrinsic toxicity, fast clearance from normal tissue and blood, and no pharmaceutical effects. In the past, boronated monoclonal antibodies have been proposed using large boron-containing molecules or dendrimers, but with no investigations in relation to maintaining antibody specificity and structural and functional features. This work aims at improving the potential of monoclonal antibodies applied to BNCT therapy, identifying in silico the best native residues suitable to be substituted with a boronated one, carefully evaluating the effect of boronation on the 3D structure of the monoclonal antibody and on its binding affinity. A boronated monoclonal antibody was thus generated for specific 10B delivery. In this context, we have developed a case study of Boron Delivery Antibody Identification Pipeline, which has been tested on cetuximab. Cetuximab is an epidermal growth factor receptor (EGFR) inhibitor used in the treatment of metastatic colorectal cancer, metastatic non-small cell lung cancer, and head and neck cancer.

Verified
Journal Article
Open access
PDF file
Paola FossaPaola Fossa
Paola Fossa
MUMatteo Uggeri
Matteo Uggeri
AOAlessandro Orro
Alessandro Orro
CUChiara Urbinati
Chiara Urbinati
Alessandro RondinaAlessandro Rondina
Alessandro Rondina
Pasqualina D'ursiPasqualina D'ursi
Pasqualina D'ursi
Cystic fibrosis is a hereditary disease mainly caused by the deletion of the Phe 508 (F508del) of the cystic fibrosis transmembrane conductance regulator (CFTR) protein that is thus withheld in the endoplasmic reticulum and rapidly degraded by the ubiquitin/proteasome system. Cystic fibrosis remains a potentially fatal disease, but it has become treatable as a chronic condition due to some CFTR-rescuing drugs that, when used in combination, increase in their therapeutic effect due to a synergic action. Also, dietary supplementation of natural compounds in combination with approved drugs could represent a promising strategy to further alleviate cystic fibrosis symptoms. On these bases, we screened by in silico drug repositioning 846 small synthetic or natural compounds from the AIFA database to evaluate their capacity to interact with the highly druggable lumacaftor binding site of F508del-CFTR. Among the identified hits, nicotinamide (NAM) was predicted to accommodate into the lumacaftor binding region of F508del-CFTR without competing against the drug but rather stabilizing its binding. The effective capacity of NAM to bind F508del-CFTR in a lumacaftor-uncompetitive manner was then validated experimentally by surface plasmon resonance analysis. Finally, the capacity of NAM to synergize with lumacaftor increasing its CFTR-rescuing activity was demonstrated in cell-based assays. This study suggests the possible identification of natural small molecules devoid of side effects and endowed with the capacity to synergize with drugs currently employed for the treatment of cystic fibrosis, which hopefully will increase the therapeutic efficacy with lower doses.

28 June 2024 in Viruses
Verified
Journal Article
Open access
PDF file
Pasqualina D'ursiPasqualina D'ursi
Pasqualina D'ursi
Alessandro RondinaAlessandro Rondina
Alessandro Rondina
AZAlberto Zani
Alberto Zani
MUMATTEO UGGERI
MATTEO UGGERI
SMSerena Messali
Serena Messali
FCFrancesca Caccuri
Francesca Caccuri
The human immunodeficiency virus (HIV-1) matrix protein p17 (p17) is released from infected cells as a protein capable of deregulating the biological activity of different cells. P17 variants (vp17s), more frequently detected in the plasma of HIV-1+ patients with rather than without lymphoma and characterized by amino acids insertions in their C-terminal region, were found to trigger B cell growth and clonogenicity. Vp17s endowed with B-cell-growth-promoting activity are drastically destabilized, whereas, in a properly folded state, reference p17 (refp17) does not exert any biological activity on B cell growth and clonogenicity. However, misfolding of refp17 is necessary to expose a masked functional epitope, interacting with the protease-activated receptor 1 (PAR-1), endowed with B cell clonogenicity. Indeed, it is worth noting that changes in the secondary structure can strongly impact the function of a protein. Here, we performed computational studies to show that the gain of function of vp17s is linked to dramatic conformational changes due to structural modification in the secondary-structure elements and in the rearrangement of the hydrogen bond (H-bond) network. In particular, all clonogenic vp17s showed the disengagement of two critical residues, namely Trp16 and Tyr29, from their hydrophobic core. Biological data showed that the mutation of Trp16 and Tyr29 to Ala in the refp17 backbone, alone or in combination, resulted in a protein endowed with B cell clonogenic activity. These data show the pivotal role of the hydrophobic component in maintaining refp17 stability and identify a novel potential therapeutic target to counteract vp17-driven lymphomagenesis in HIV-1+ patients.

26 June 2026 in SSRN Electronic Journal
Verified
Preprint
Open access
VCViviana Cristillo
Viviana Cristillo
TMTommaso Merati
Tommaso Merati
CTChiara Tolassi
Chiara Tolassi
Alessandro RondinaAlessandro Rondina
Alessandro Rondina
VBValentina Bettonagli
Valentina Bettonagli
APAlessandro Padovani
Alessandro Padovani
BackgroundMultiple sclerosis (MS) is characterized by inflammatory demyelination, neuroaxonal injury and progressive neurodegeneration. The biological processes driving the disease are already active at clinical onset, yet comprehensive characterization of different molecular pathways at diagnosis remains limited. ObjectiveTo integrate high-sensitivity CSF biomarker profiling with clinical disability measures, MRI lesion burden, and microstructural diffusion metrics in normal-appearing white matter (NAWM) in treatmentnaïve new diagnosed Multiple Sclerosis patients.MethodsCSF samples were collected from 70 treatment-naïve newly diagnosed MS patients and 11 age- and sex-matched healthy controls. A CNS Disease Panel of 120 CSF biomarkers was quantified using ultra-sensitive NULISA technology. Differential expression analysis was performed using false discovery rate (FDR) correction. Multivariable linear regression models adjusted for age, sex, and ethnicity were used to evaluate associations with baseline Expanded Disability Status Scale (EDSS), short-term clinical change after high-dose corticosteroid therapy (ΔEDSS) and MRI white matter lesion volume. Partial correlation analyses were performed to assess associations between CSF and diffusion MRI measures in NAWM regions of interest.ResultsSeven biomarkers were significantly increased in MS compared with controls after FDR correction: REST, IL-16, CHI3L1, NEFL, ICAM-1, TREM2, and CHIT1. Correlation analysis demonstrated clustering among markers of glial and innate immune activation (CHI3L1, TREM2, CHIT1) and moderate associations between NFL and glial markers. REST was strongly correlated with IL16, suggesting early transcriptional and immune pathway interplay.In multivariable models, higher levels of glial activation markers were independently associated with greater baseline disability. CSF NFL levels correlated with white matter lesion burden and were significantly associated with diffusion abnormalities in NAWM, particularly in the genu of the corpus callosum, cingulum, and anterior corona radiata, indicating that neuroaxonal injury reflects both focal inflammatory activity and diffuse microstructural damage beyond visible lesions.DiscussionThis application of ultra-sensitive NULISA multiplex CSF profiling in treatment-naïve MS at diagnosis demonstrates that multiple immunological and neurodegenerative pathways are simultaneously active at disease onset and are associated with early disability and microstructural white matter damage. These findings support the concept that inflammatory and neurodegenerative processes occur in parallel early in MS and suggest that integrated CSF biomarker profiling may improve early disease characterization.ConclusionsMultiplex CSF proteomic profiling using NULISA identifies biologically meaningful biomarker signatures at MS disease onset. Integration of multiplex biomarkers with clinical and imaging measures may improve early disease stratification and support personalized therapeutic strategies.

24 June 2026 in medRxiv
Verified
Preprint
Open access
TMTommaso Merati
Tommaso Merati
CTChiara Tolassi
Chiara Tolassi
Alessandro RondinaAlessandro Rondina
Alessandro Rondina
IGIrene Girotto
Irene Girotto
MBMarianna Bertoni
Marianna Bertoni
APAlessandro Padovani
Alessandro Padovani
Blood-based proteomic profiling is now widely applied in neurodegenerative and neuroinflammatory disease, yet the choice between serum and plasma remains poorly characterised for high-multiplex platforms. Many legacy biobanks hold mainly serum, whereas most current NUcleic-acid-Linked Immuno-Sandwich Assay (NULISA) studies use plasma. We compared the 130-protein NULISAseq central nervous system (CNS) Disease Panel head-to-head in matched serum and plasma collected at the same draw from 62 participants (30 neurodegenerative, 19 demyelinating, 13 healthy controls). Agreement was measured with Spearman correlation (rho), Lin’s concordance correlation coefficient (CCC), the intraclass correlation coefficient (ICC) and the mean paired serum-to-plasma difference (dNPQ). Concordance was moderate to high: 123 of 130 proteins reached significance and 18 reached rho >= 0.90, with a median rho of 0.72 (range 0.10-0.988). Proteins fell into three tiers. Cytoskeletal markers (NEFH rho=0.988; NEFL rho=0.947) and glial GFAP (rho=0.949, |dNPQ|<0.5) were interchangeable between matrices. Phosphorylated tau (pTau) species retained excellent rank concordance but carried a systematic plasma-greater-than-serum offset (pTau-181 rho=0.869, dNPQ=+0.67; pTau-217 rho=0.846, dNPQ=+0.64; pTau-231 rho=0.885, dNPQ=+0.89). Platelet-derived analytes (CD40LG rho=0.102, dNPQ=-4.74; BDNF rho=0.223, dNPQ=-2.69) and intracellular synaptic proteins (NRGN, SNAP25, ENO2) diverged markedly. For most clinically relevant neurodegeneration markers, especially cytoskeletal and glial proteins, serum is a valid substitute for plasma; absolute thresholds for phosphorylated tau and amyloid peptides require matrix-specific calibration, and platelet-sensitive analytes cannot be compared across matrices without strictly standardised pre-analytical conditions. Main Points: Across the 130-protein NULISAseq CNS Disease Panel, serum and plasma showed moderate-to-high overall concordance (median Spearman rho 0.72; 123/130 proteins significant). Neurofilaments (NEFH, NEFL) and GFAP were interchangeable between matrices, whereas phosphorylated tau species retained rank order but required matrix-specific calibration of absolute levels. Platelet-derived (CD40LG, BDNF) and intracellular synaptic proteins (NRGN, SNAP25, ENO2) were not comparable across matrices without strict pre-analytical standardisation.